Sugi Predict

Sugi Predict / Compounds / Oxyquinoline

Oxyquinoline

Oxyquinoline

SCHEMBL249778

O=S(=O)(O)C(F)(F)F.Oc1cccc2cccnc12

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.81
▸ ALOX12 P18054 2/20 0.81
▸ COMT P21964 2/20 0.70
▸ MMP2 P08253 2/20 0.70
▸ TSHR P16473 2/20 0.70
▸ CHRM1 P11229 1/20 0.70
▸ ADRA1A P35348 1/20 0.70
▸ METAP2 P50579 1/20 0.70
▸ METAP1 P53582 1/20 0.70
▸ HDAC8 Q9BY41 1/20 0.70
▸ ALDH1A1 P00352 3/20 0.56
▸ LMNA P02545 3/20 0.56
▸ MAPK1 P28482 2/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ TDP1 Q9NUW8 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyquinoline SCHEMBL29598375 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL29358129 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL29390000 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL48928 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL324753 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL406261 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL11030474 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL11030477 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL9625423 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR
Oxyquinoline SCHEMBL11030481 0.90 KDM4E (1.00) KDM4EALOX12COMTMMP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102219736-B Preparation method for 8-quinolinecarboxylic ester and 8-quinolinecarboxylic acid JW & Y SHANGHAI PHARMLAB CO LTD 2012-12-19 — — CN disclosed
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 — — EP disclosed
CN-102219736-A Preparation method for 8-quinolinecarboxylic ester and 8-quinolinecarboxylic acid JW & Y SHANGHAI PHARMLAB CO LTD 2011-10-19 — — CN disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 — — EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 — — US disclosed
US-20040053890-A1 Naphthalene derivatives NOVARTIS AG (CH) 2004-03-18 — — US disclosed
EP-1339663-A2 NAPHTHALENE DERIVATIVES Novartis AG (CH) 2003-09-03 — — EP disclosed
WO-2002042248-A2 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053890-A1 Naphthalene derivatives CYP1A1, SULT1E1, CYP2F1 KDM4E 3981/4885ALOX12 2178/4885COMT 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.